Cjc1295-Ipa

CJC-1295/Ipamorelin combines CJC-1295, a synthetic long-acting analog of growth hormone-releasing hormone (GHRH), with Ipamorelin, a selective pentapeptide agonist of the ghrelin receptor (GHS-R1a). The pairing is studied in preclinical and early-phase research on growth hormone/IGF-1 axis activation, pituitary somatotroph signaling, and receptor-selective secretagogue pharmacology.
Studied for (preclinical / in vitro research):
• Dose-dependent GH and IGF-1 elevation via GHRH-receptor/Gs/cAMP/PKA signaling in Phase I dose-escalation research (Teichman et al., 2006)
• Preservation of pulsatile GH secretion during continuous GHRH-receptor stimulation (Alba et al., 2006)
• Albumin-bioconjugation (DAC) mechanism extending peptide half-life to approximately 6-8 days in pituitary GRF-receptor activation studies (Jetté et al., 2005)
• Selective ghrelin receptor (GHS-R1a) binding and GH-releasing potency comparable to GHRP-6 in rat and swine models (Raun et al., 1998)
• Minimal cortisol, ACTH, and prolactin stimulation relative to earlier-generation GH secretagogues in receptor-selectivity profiling
• Longitudinal bone growth and bone mineral content changes in rodent GH-axis research
• Serum proteomic biomarker changes associated with GH/IGF-1 axis activation (Sackmann-Sala et al., 2009)

For Laboratory Research Use Only. Not for human or veterinary use. Not a drug, dietary supplement, or cosmetic. Not intended to diagnose, treat, cure, or prevent any disease. Not for in-vivo use of any kind outside of a controlled research setting. Keep out of reach of children. By purchasing, you certify that you are a qualified researcher or research institution acquiring this product solely for in vitro laboratory research, and that you accept sole responsibility for compliance with all applicable local, state, and federal laws and regulations.